3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
16
OTHER_GOV
1
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Glioblastoma
18
Carcinoma, Non-Small-Cell Lung
6
Glioma
5
Brain Neoplasms
5
Head and Neck Neoplasms
4
Neoplasms
3
Neoplasm Metastasis
3
Melanoma
3
Esophageal Neoplasms
3
Carcinoma, Squamous Cell
3
Breast Neoplasms
3
Astrocytoma
3
Stomach Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Pain
2
Lung Neoplasms
2
Gliosarcoma
2
Central Nervous System Neoplasms
2
Bone Neoplasms
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Stomatitis
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms by Site
1
Interventions
Paclitaxel
18
pembrolizumab
16
Cisplatin
16
Fluorouracil
15
Irinotecan
13
tislelizumab
9
Oxaliplatin
8
Nivolumab
8
Docetaxel
8
Leucovorin
6
Capecitabine
5
spartalizumab
4
Levoleucovorin
4
Carboplatin
4
lenvatinib
3
durvalumab
3
Radiotherapy
3
Drug Therapy
3
toripalimab
2
sintilimab
2
regorafenib
2
elgemtumab
2
atezolizumab
2
Itraconazole
2
Injections
2
Gemcitabine
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
sitravatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Esophageal Squamous Cell Carcinoma
×
Radiation
×
Clear all
NCT04550260
2026-05-13
KUNLUN
AstraZeneca
Phase 3
Active not recruiting
640 enrolled